2019年1-8月，医药行业主要运行指标呈现以下特点:一是行业固定资产投资保持增长，投资额同比增长7.4%;二是医药行业工业增加值累计增速为6.9%; 三是行业零售额继续保持较高增速，累计增速为10. 6%; 四是医药行业营业收入和利润保持增长，营业务收入和利润总额同比增长分别为8.5%和9.5%。.

2019年1-7月，医药行业主要运行指标呈现以下特点:一是行业固定资产投资保持增长，投资额同比增长6. 9%;二是医药行业工业增加值累计增速为6.7%; 三是行业零售额继续保持较高增速，累计增速为11. 1%; 四是医药行业营业收入和利润保持增长，营业务收入和利润总额同比增长分别为8.9%和9.3%。

『互联网医疗』行业背景：我国医疗服务总量不足。近年来我国医疗服务供给已逐步加大，但未来国民对医疗服务的需求将只增不减。

2019年1-6月，医药行业主要运行指标呈现以下特点:一是行业固定资产投资继续增加,投资额同比增长8.4%:二是医药行业工业增加值增速小幅下降，累计增速为6.6%;三是行业零售额继续保持较高增速，累计增速为10. 9%；四是医药行业营业收入和利润保持增长，营业务收入和利润总额同比增长分别为8.5%和9.4%。

截止2019年10月底，我国医药行业规模以上企业数量达到7323家，其中亏损企业数量1284家，亏损面17.5%，环比下降0.3个百分点。2019年1-10月 全年医药行业亏损总额106.3亿元，同比减少10. 8%。

截止2019年9月底，我国医药行业规模以上企业数量达到7321家，其中亏损企业数量1304家，亏损面17. 8%，环比下降0. 1个百分点。2019年1-9月 全年医药行业亏损总额97.1亿元，同比减少12.9%。

截止2019年7月底，我国医药行业规模以上企业数量达到7309家，其中亏损企业数量1322家，亏损面18.1%， 环比下降2个百分点。2019年1-7月 全年医药行业亏损总额81.3亿元，同比减少10.1%。

截止2019年11月底，我国医药行业规模以上企业数量达到7346家，其中亏损企业数量1247家，亏损面17.0%， 环比下降0. 6个百分点。2019年1-11月全年医药行业亏损总额123.0亿元，同比减少5. 8%。

发展历程：步入行业整合期，未来竞争业态多元化借助各类电商模式成熟的东风，医美电商为期不到十年，整体市场已进入行业整合期，形成以新氧为龙头企业的稳定局面。下一阶段的竞争会更加激烈，马太效应凸显。

2019年1-9月，医药行业主要运行指标呈现以下特点:一是行业固定资产投资保持增长，投资额同比增长7. 0%;二是医药行业工业增加值累计增速为6.9%; 三是行业零售额继续保持较高增速，累计增速为10. 1%; 四是医药行业营业收入和利润保持增长，营业务收入和利润总额同比增长分别为8. 4%和.10.0%。

本监测报告内容覆盖智能制造装备总体产业，包括智能测控装置、关键基础零部件、智能化高端装备和重大集成智能装备等智能制造装备的细分产业；以关键制造环节的智能化为核心，以端到端数据流为基础，和以网通互联为支撑。包括智能 产品、智能生产、智能工厂、智能物流、各类智能机器人等。

截止2019年8月底，我国医药行业规模以上企业数量达到7307家，其中亏损企业数量1310家，亏损面17.9%，环比下降0.2个百分点。2019年1-8月全年医药行业亏损总额93.7亿元，同比减少8.0%。

The high prevalence of TB in India has led to the development of many new initiatives for quick and efficient diagnosis. The TB prevalence rate is high in countries, like China, India, and Africa. Hence, the governments of these respective countries are trying to decrease the rate, by increasing government initiatives and hospitals. The United States continued to make slow progress toward TB elimination, as CDC played an important role in TB elimination, by working with state and local partners in the United States. The US government also focused on strengthening support for laboratory accreditation as a means of assuring high-quality TB diagnostic service, with highly efficient diagnostic tools. Sputum smear microscopy test has been the most commonly used test for the diagnosis of pulmonary TB in low- and middle-income countries. This is a simple, rapid, and inexpensive technique, which is highly specific in areas with a very high prevalence of tuberculosis. Another laboratory test includes the culture-based test for the diagnosis of TB, which remains the gold standard for the diagnosis of pulmonary tuberculosis, mainly in the developing countries.

Orphan drugs can be defined as a molecule intended to treat a rare disease. The rare disease, as name suggests, has low prevalence rate and has been defined differently across the geographical locations. Each country has at the least one organization, which has been supporting the patients suffering from rare diseases. The need is to generate enough orphan drugs’ availability to the needful for the intended treatment, across the world. From the company's perspective, there is increased focus by drug manufacturers, each year, on the development of therapies for orphan indications, as well as, explore the expansion opportunities across the world. The market report discusses the market aspects related to each market, segmentation, and major geographies across world. The market size can be evaluated by collating the revenues generated from various segments and their usage across the various end-user industries, along with the costs associated with products. The definitions for individual segments have been provided in the respective segments. The market estimates provided in this report are entirely based on the segments tracked in this report.

Pap and HPV tests are vital for diagnosis of cancers and precancer stages in cervix. Mostly these tests are performed together for the patient age group between 21-65 years. As per the international Agency for Research on Cancer, more than 85% of cervical cancer patients are from the developing countries, which demands better efficacy screening and treatment programs for women’s health. Since the cancer progression is slow and may take up to 20 years to develop into an advanced stage, there are many opportunities to stop the disease before it becomes fatal. At present, there are many cities in the emerging market that lack resources for a good laboratory with highly trained cytotechnicians and other specialized staff, which is among the major challenges for good results from Pap testing. With the advancement of HPV tests, the prevention possibility of expansion of cervical cancers increases even in the low resource settings because it is a more affordable and cost-effective strategy, leveraging self-sampling potentially. There are countries, such as Australia and New Zealand, which have effectively taken positive measures related to proper HPV and Pap testing to eradicate cervical cancer. However, the current scenario demands more countries to take better initiatives to roll out the advanced screening tests of HPV and Pap through financial support from the government.

The market for medical electrodes is being driven by factors, such as the increasing prevalence of cardiovascular and neurological diseases, increasing investm ent for technological a dvancemen ts by biopharmaceutical companies, and rising focus toward minimally invasive surgeries. The rising population of the world is stimulating the demand for increased access and advancements in diagnostic technologies and treatment modalities. Due to the aging and rising world population, the demand for healthcare products and services increased by multiple times in the past decade, particularly in the developed and high-economic growth countries. The growing prevalence of cardiac and neurological diseases plays an essential role in the growth of the medical electrodes market.

Evidence-based research studies on healthcare technologies indicated that the adoption of patient portals reached 90% in most of the developed countries. This means, 90% of the providers offer patient portals to their patients in the United States. However, there are still some unmet needs of the patients that require more actions, in order to drive the effective use of patient portals across the developing countries. Despite the higher adoption rate of patient portals, the number of patients that use the portal to take care of their health is low. According to a report published by the American Hospital Association (AHA), only 30% of the patients in the United States actively use patient portal. The scenario is similar in the European countries, such as Germany and France, where the adoption is higher, but the actual use is yet to reach the satisfactory percentage.